Drug Profile


Alternative Names: Alsertib; Aurora A inhibitor; MLN-8237

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Millennium Pharmaceuticals
  • Developer Fox Chase Cancer Center; Massachusetts General Hospital; Millennium; National Cancer Institute (USA); Ohio State University Comprehensive Cancer Center; Takeda Oncology; UNC Lineberger Comprehensive Cancer Center; University of Texas M. D. Anderson Cancer Center; Weill Cornell Medical College
  • Class 3-ring heterocyclic compounds; Antineoplastics; Azepines; Benzazepines; Benzoic acids; Fluorobenzenes; Phenyl ethers; Pyrimidines; Small molecules
  • Mechanism of Action Aurora kinase A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; B cell lymphoma; Brain cancer; Mesothelioma; Prostate cancer; Small cell lung cancer
  • Phase I/II Gynaecological cancer; Non-small cell lung cancer; Solid tumours
  • Phase I Breast cancer; Burkitt's lymphoma; Cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Gastric cancer; Lymphoma; Non-Hodgkin's lymphoma; Oesophageal cancer
  • Discontinued Myelodysplastic syndromes; Ovarian cancer; Peripheral T-cell lymphoma

Most Recent Events

  • 26 Apr 2017 Millennium Pharmaceuticals and UNC Lineberger Comprehensive Cancer Center suspends patient enrolment in a phase I/Ib trial due to pending transfer of IND to another institution for Diffuse large B-cell lymphoma, Follicular lymphoma and Burkitt's lymphoma (Combination therapy, Late-stage disease, Metastatic disease, Newly diagnosed) in USA (PO) (NCT02700022)
  • 01 Mar 2017 Millenium Pharmaceuticals terminates a phase I trial due to business decision in Solid tumours, gastric cancer and oesophageal cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Spain, USA (PO, Tablet) (NCT02551055)
  • 01 Jan 2017 Millennium Pharmaceuticals completes a phase I trial for Prostate cancer (Combination therapy, Late-stage disease, Hormone-refractory) in USA (NCT01094288)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top